CD13 and CD33 were the most frequently expressed aberrant markers in patients with ALL, whereas CD7 and CD19 were the most frequently expressed aberrant markers in patients with acute myeloid leukemia. Here, CD19 is linked to acute lymphoblastic leukemia.